 SAN DIEGO and TORONTO, Oct. 18, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September 30, 2022, on Tuesday, November 1, 2022 after the close of the market, and provide a corporate update. 